CEO Ian Bothwell Discloses 40.2% Voting Control in Zeo ScientifiX
ZEOX sits 92% above its 52-week low of $1.2 on elevated volume (2.9× avg).
Summary
Zeo ScientifiX CEO Ian T. Bothwell updated his beneficial ownership, now holding 14.7% of common stock and an additional 25.5% of voting power through preferred stock, totaling 40.2% of the company's voting power.
Key Events · Ownership and Investor Activity · ZEOX
-
Significant Voting Control
CEO Ian T. Bothwell now beneficially owns 14.7% of the common stock and an additional 25.5% of voting power through Series C Preferred Stock, resulting in an aggregate 40.2% of the company's total voting power.
-
Increased Common Stock Holdings
His beneficial ownership of common stock increased to 1,195,094 shares, including 87,500 restricted shares vesting July 14, 2026, 187,500 shares from warrants, and 180,000 shares from options.
-
Equity Grants Reported
The increase in common stock holdings since the last filing is primarily due to a grant of 55,000 stock options on May 8, 2025, and 175,000 restricted shares on January 14, 2026, both at a $0.00 price.
Analysis · ZEOX · Life Sciences
This Schedule 13D/A filing updates the beneficial ownership of CEO, CFO, and Director Ian T. Bothwell, revealing he now controls a substantial 40.2% of the company's total voting power. This level of concentrated insider control is a critical factor for investors, as it grants significant influence over corporate decisions and strategic direction. The increase in his common stock holdings since the last filing is primarily due to recent compensation grants.
At the time of this filing, ZEOX was trading at $2.30 on OTC in the Life Sciences sector, with a market capitalization of approximately $17.9M. The 52-week trading range was $1.20 to $3.32. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.